skip to Main Content

New potent switch for expression of biotherapeutics

Cologne/ Bonn/ Bayreuth, 7 October 2024 – 

In a significant leap forward for biotechnological research, a cutting-edge light-sensitive expression system, termed DEL-VPR, was recently developed by Ningaloo Biosystems in collaboration with the research groups of Prof. Dr. Dagmar Wachten (University of Bonn) and Prof. Dr. Andreas Möglich (University of Bayreuth). This novel system offers unprecedented precision in the modulation of gene expression through light-dependent activation.

The DEL-VPR technology is based on a blue light-sensitive photoswitch derived from the Erythrobacter litoralis’ EL222, coupled with three potent transcriptional activator domains: VP64, p65, and Rta. This combination enables highly controlled, light-dose-dependent gene expression and achieving expression levels comparable to well-established constitutive promoters such as CMV. With DEL-VPR, researchers can fine-tune the production of complex biopharmaceuticals, including monoclonal and bispecific antibodies, offering new possibilities for optimizing therapeutic protein production.

The system not only simplifies experimental workflows but also enhances precision, opening up new frontiers in biopharmaceutical research. Its innovative approach allows for the modulation of intricate processes in real time, offering significant advantages in areas like drug development and synthetic biology. For more details, visit our recent [bioRxiv publication]. Interested researchers can request the DEL-VPR photoswitch for their own studies through a Material Transfer Agreement (MTA).

Back To Top